887950-87-0

Upstream product

• 4746-97-8 cyclohexanedione monoethylene ketal 
• 6952-59-6 3-cyanobromobenzene 
• 540787-52-8 4-(3-cyanophenyl)-4-hydroxycyclohexan-1-one ethylene ketal 

Downstream Products

• 540781-58-6 N'-(4-fluoro-3-trifluoromethyl-phenyl)-N-[4-(3-cyanophenyl)-4-hydroxycyclohexyl]-N-[2-(1-pyrrolidinyl)ethyl]urea 
• 540787-50-6 1-[2-(1-pyrrolidinyl)ethylamino]-4-(3-cyanophenyl)-4-hydroxycyclohexane 

Relevant academic research and scientific papers

Overcoming hERG activity in the discovery of a series of 4-azetidinyl-1-aryl-cyclohexanes as CCR2 antagonists

A series of 4-azetidinyl-1-aryl-cyclohexanes as potent CCR2 antagonists with high selectivity over activity for the hERG potassium channel is discovered through divergent SARs of CCR2 and hERG.

4-AZETIDINYL-1-PHENYL-CYCLOHEXANE ANTAGONISTS OF CCR2

The present invention comprises compounds of Formula (I): wherein: X, R1, R2, R3, and R4 are as defined in the specification. The invention also comprises a method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is type II diabetes, obesity and asthma. The invention also comprises a method of inhibiting CCR2 activity in a mammal by administration of a therapeutically effective amount of at least one compound of Formula (I).

Bicyclic[4.1.0]heptanes as phenyl replacements for melanin concentrating hormone receptor antagonists

Melanin concentrating hormone (MCH) receptor antagonists have been proposed as potential treatments of obesity. MCH receptor antagonists with a biphenylamine subunit have been reported previously at Schering-Plough. Herein, we report the discovery of bicy